Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors

Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor types. Biomarkers are biological indicators used to select patients for a systemic anticancer treatment, but there are only a few clinically useful biomarkers such as PD-L1 expression and tumor mutational burden, which can be used to predict immunotherapy response. In this study, we established a database consisting of both gene expression and clinical data to identify biomarkers of response to anti-PD-1, anti-PD-L1, and anti-CTLA-4 immunotherapies. A GEO screening was executed to identify datasets with simultaneously available clinical response and transcriptomic data regardless of cancer type. The screening was restricted…

• SE
  Semmelweis Egyetem
• NK
  Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

  Award: PALY-2021
• NR
  National Research, Development and Innovation Office

  Awards: RRF-2.3.1-21-2022-00015, PharmaLab, RRF-2.3.1-21-2022-00015, 2020-1.1.6-JÖVŐ-2021-00013